CXCL10/IP-10/CRG-2 Antibody (984429) [Unconjugated]

CXCL10/IP‑10/CRG‑2 was detected in immersion fixed paraffin-embedded sections of human tonsil using Mouse Anti-Human CXCL10/IP‑10/CRG‑2 Monoclonal Antibody (Catalog # MAB2662) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in endothelial cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

• Reactivity: Hu
• Applications: IHC
• Clone: 984429
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

CXCL10/IP-10/CRG-2 Antibody (984429) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human CXCL10/IP-10/CRG-2
  Val22-Pro98
  Accession # P02778.2
• Specificity: Detects human CXCL10/IP-10/CRG-2 in direct ELISAs.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL10/IP-10/CRG-2 Antibody (984429) [Unconjugated]

• C7
• chemokine (C-X-C motif) ligand 10
• CRG2
• CRG-2
• CXCL10
• gIP-10
• IFI10
• INP10
• IP-10
• mob-1
• SCYB10

Background

CXCL10 was originally identified as an IFN-gamma -inducible gene in monocytes, fibroblasts and endothelial cells. It has since been shown that CXCL10 mRNA is also induced by LPS, IL-1 beta, TNF‑ alpha, IL-12 and viruses. Additional cell types that have been shown to express CXCL10 include activated T‑lymphocytes, splenocytes, keratinocytes, osteoblasts, astrocytes, and smooth muscle cells. CXCL10 is also expressed in psoriatic and lepromatous lesions of skin. The mouse homologue of human CXCL10, Crg-2, has been cloned and shown to share approximately 67% amino acid sequence identity with human CXCL10. Human CXCL10 cDNA encodes a 98 amino acid (aa) residue precursor protein with a 21 aa residue signal peptide that is cleaved to form the 77 aa residue secreted protein. The amino acid sequence of CXCL10 identified the protein as a member of the chemokine alpha subfamily that lacks the ELR domain. CXCL10 has been shown to be a chemoattractant for activated T‑lymphocytes. CXCL10 has been reported to be a potent inhibitor of angiogenesis and to display a potent thymus-dependent antitumor effect. A chemokine receptor specific for CXCL10 and Mig has been cloned and shown to be highly expressed in IL-2-activated T‑lymphocytes.

1. Loetscher, M. et al. (1996) J. Exp. Med. 184:963.
2. Wang, X. et al.(1996) J. Biol. Chem. 271:24286.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P02778.2()